

Jyothy Laboratories

Estimate change

TP change

Rating change



Motilal Oswal values your support in the Asiamoney Brokers Poll 2023 for India Research, Sales, Corporate Access and Trading team. We request your ballot.



Bloomberg	JYL IN
Equity Shares (m)	367
M.Cap.(INRb)/(USDb)	106.7 / 1.3
52-Week Range (INR)	291 / 164
1, 6, 12 Rel. Per (%)	32/33/55
12M Avg Val (INR M)	110

Financials & Valuations (INR b)

Y/E March	2023	2024E	2025E
Net Sales	24.9	28.1	31.2
Sales Gr. (%)	13.2	12.9	11.1
EBITDA	3.2	4.3	5.0
EBITDA Margins (%)	12.7	15.5	16.1
Adj PAT	2.3	3.2	3.7
Adj.EPS (INR)	6.3	8.7	10.1
EPS Gr. (%)	46.2	37.3	16.6
BV/Sh (INR)	42.2	45.9	49.5
Ratios			
RoE (%)	15.6	19.8	21.3
RoCE (%)	15.7	20.4	22.0
Payout (%)	57.3	55.6	64.4
Valuation			
P/E (x)	45.9	33.4	28.6
P/BV (x)	6.9	6.3	5.9
EV/EBITDA	32.9	23.8	20.1
Div. Yield (%)	1.0	1.4	1.9

Shareholding pattern (%)

As On	Jun-23	Mar-23	Jun-22
Promoter	62.9	62.9	62.9
DII	15.4	16.8	18.1
FII	14.0	13.8	11.5
Others	7.8	6.5	7.5

FII Includes depository receipts

CMP: INR291 TP: INR305 (+5%) Neutral

Operating margin surprises positively; gaining market share

- Jyothy Laboratories (JYL) reported an overall beat on our estimates in 1QFY24. It gained market share with volume growth of 9%. JYL reported EBITDA margin of 17.1% (est. 14.6%), led by moderation in input costs. GP margin came back to the normal level at 47.9% (est. 45.8%).
- The likelihood of 17% EBITDA margin for further quarters appears to be difficult as the company has guided for 15-16% margin for FY24 and volatility in RM prices.
- Other income included a one-off item of ~INR90m on land sale at a plant.
- Despite good results in 1QFY24 (albeit on a low margin base of 1QFY23), JYL's sales and EBITDA CAGRs for five years ending in FY24E are expected to remain in single digits. We maintain our **Neutral** rating on the stock.

An all-round beat on estimates

- Standalone net sales grew 15.1% YoY to INR6,864m (est. INR6,411m).
- Volume growth was 9%.
- EBITDA increased by 96.2% YoY to INR1175m (est. INR936m).
- PBT rose 134% YoY to INR1,124m (est. INR838m).
- Adj. PAT was up 124% YoY at INR874m (est. INR659m).
- Gross margin expanded ~800bp YoY to 47.9%. EBITDA margin gained ~710bp YoY to 17.1%.

Consolidated segmental performance

- Fabric Care/Dishwashing/Household Insecticides/Personal Care sales rose 18.1%/10.6%/10.1%/21.1% YoY to INR2,966m/INR2,315m/INR494m/INR841m in 1QFY24.
- Margins in Fabric Care/Dishwashing/Personal Care expanded 980bp/690bp/150bp YoY to 22.1%/20%/18.2%, but contracted 900bp YoY to -19% in Household Insecticides.

Highlights from the management commentary

- In 1Q, JYL increased prices by 6% and posted volume growth of 9%.
- The management has guided for double-digit revenue growth in FY24, led by volume growth.
- The management expects EBITDA margin of 15-16% in FY24.
- Other Income included a one-off item of ~INR90m on land sale at a plant.
- Seasonal variations and illegal incense sticks impact HI demand.

Valuation and view

- We raise our EPS Estimates for FY24/FY25 by 8%/5%.
- For a company that had lower sales of INR24.9b in FY23 (vs. its peers), its performance over the past five years has been consistently lackluster (at 8.3%/4.2% sales/operating profit CAGR).
- Despite healthy EBITDA growth in 1QFY24, JYL's EBITDA CAGR for the 3 years and 5 years ending in FY24 is expected to remain in single digits. Despite assuming consolidated EBITDA margins close to their peak level in FY25, RoE remains lower than peers' at ~21%.

Pratik Bipinchandra Prajapati - Research Analyst (Pratik.Prajapati@MotilalOswal.com)

Tanu Jindal – Research Analyst (Tanu.Jindal@MotilalOswal.com)

We do not expect a major rerating anytime soon. We reiterate our Neutral stance on the stock with a TP of INR305 (21xFY25E target EV/ EBITDA).

Standalone Quarterly Perfo	rmance											(INR m)
Y/E March		FY2	3			FY2	4				FY24	Var.
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY23	FY24E	1QE	(%)
Net Sales	5,965	6,464	6,117	6,159	6,864	7,150	6,985	6,867	24,860	28,060	6,411	7.1
YoY change (%)	14.3	11.8	15.7	12.8	15.1	10.6	14.2	11.5	13.2	12.9	9.4	
Gross Profit	2,378	2,563	2,636	2,815	3,287	3,382	3,220	3,104	10,511	13,067	2,936	11.9
Margins (%)	39.9	39.6	43.1	45.7	47.9	47.3	46.1	45.2	42.3	46.6	45.8	4.5
EBITDA	599	802	843	906	1,175	1,151	1,062	1,016	3,159	4,340	936	25.6
EBITDA growth %	-7.9	19.5	39.3	58.2	96.2	43.6	25.9	12.2	26.4	37.4	56.5	
Margins (%)	10.0	12.4	13.8	14.7	17.1	16.1	15.2	14.8	12.7	15.5	14.6	
Depreciation	130	112	122	119	120	151	164	179	501	626	153	
Interest	33	12	32	31	11	32	35	35	131	137	30	
Other Income	44	55	152	62	79	91	99	102	395	417	85	
PBT	480	733	842	817	1,124	1,059	962	904	2,922	3,995	838	34.1
Tax	90	109	168	227	250	211	188	176	595	799	178	
Rate (%)	18.7	14.9	20.0	27.8	22.3	19.9	19.5	19.5	19.9	20.0	21.3	
Adjusted PAT	390	624	674	590	874	848	774	728	2,327	3,196	659	32.5
YoY change (%)	-2.7	48.0	90.4	77.2	123.9	36.0	14.9	23.4	54.2	37.3	52.0	

E: MOFSL Estimates

Key Performance Indicators

Y/E March			FY24		
	1Q	2Q	3Q	4Q	1Q
2Y average growth %					
Sales	18.0	13.8	14.2	12.4	14.7
EBITDA	-12.4	-2.5	7.6	20.1	44.2
PAT	-11.6	8.7	29.1	21.6	60.6
% sales					
COGS	60.1	60.4	56.9	54.3	52.1
Other expenditure	29.8	27.2	29.3	31.0	30.8
Depreciation	2.2	1.7	2.0	1.9	1.7
YoY change %					
COGS	20.8	11.9	11.7	4.6	-0.3
Other expenditure	11.2	8.4	14.6	12.9	18.7
Other income	-8.9	5.5	258.6	11.0	80.0
EBIT	5.5	48.2	82.5	120.1	125.1

E: MOFSL Estimates



Highlights from the management commentary

Performance and outlook

- JYL has witnessed a stable demand environment with moderated input costs.
- In 1Q, it increased prices by 6% and reported 9% volume growth.
- The management expects double-digit revenue growth in FY24, led by volume growth.
- The ratio of sales volume in rural vs. urban was 40:60 in 1Q.
- Rural market impacted by inflation has shown signs of recovery.
- The company focuses on LUPs and rural distribution to recover sales in the rural market.
- LUPs' contribution is around 25-30% of total volume.
- The company's pricing strategy has received good response from customers and places the company to a premium pricing vs. competitors.
- The management does not expect any weather impact on the demand-supply chain.

Costs and margins

- JYL expects EBITDA margin of 15-16% in FY24.
- The softening in raw material prices helps in GP margin expansion.
- Media spending stood at 7-8% of sales in 1QFY24.
- Raw material prices have come down but are still at the elevated level and remain volatile.
- Other Income included a one-off item of ~INR90m related to land sale of a plant.

Segmental details

Fabric Care

- Expanded distribution reach increases sales across India..
- Launched Ujala liquid detergent to strengthen its premium portfolio
- Cut prices in some products

Dishwashing

- LUP's bar category gaining acceptance in the rural market.
- Focus on the larger pack in dishwash liquid category
- JYL aims for double-digit growth.

Household Insecticides

- Seasonal variations and illegal incense sticks impacting demand
- Focus on Liquid vaporizers and coils as safer options for illegal incense sticks
- The contribution ratio of Coil and LV was 60:40 in 1QFY24
- Increases media spending for the category

Personal Care

- Original Margo Neem contributed more to growth in 1QFY24 compared to new launches
- Increase in distribution, rural penetration and seasonality supported growth.

Other points

■ It expects to increase its total reach by ~100k outlets in FY24.

 $Motilal\ Oswal$ Jyothy Laboratories

Key exhibits

Exhibit 1: Consolidated quarterly performance

Category sales (INR m)	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24
Fabric Care	2,511	2,862	2,635	2,553	2,966
Dishwashing	2,093	2,279	2,213	2,062	2,315
Household Insecticides	448	435	434	800	494
Personal Care	694	733	591	524	841
Other Products	225	284	253	230	256
Total	5,972	6,592	6,127	6,170	6,871
Category salience (%)					
Fabric Care	42.0	43.4	43.0	41.4	43.2
Dishwashing	35.1	34.6	36.1	33.4	33.7
Household Insecticides	7.5	6.6	7.1	13.0	7.2
Personal Care	11.6	11.1	9.7	8.5	12.2
Other Products	3.8	4.3	4.1	3.7	3.7
Total	100.0	100.0	100.0	100.0	100.0
Category growth (%)					
Fabric Care	38.6	33.6	26.0	20.1	18.1
Dishwashing	9.6	5.6	10.0	8.7	10.6
Household Insecticides	(37.5)	(30.7)	(15.6)	0.9	10.1
Personal Care	2.1	10.8	11.6	12.1	21.1
Other Products	67.6	7.3	3.7	25.8	13.6
Total	13.7	12.6	13.7	12.8	15.1
Category results (INR m)					
Fabric Care	308	433	485	499	656
Dishwashing	275	352	338	361	463
Household Insecticides	(45)	(79)	(69)	(9)	(94)
Personal Care	25	74	90	70	153
Other Products	(10)	(15)	(15)	(8)	5
Total	554	765	830	912	1,184
Result salience (%)					
Fabric Care	55.7	56.6	58.5	54.7	55.4
Dishwashing	49.7	46.0	40.8	39.6	39.1
Household Insecticides	(8.1)	(10.4)	(8.3)	(1.0)	(7.9)
Personal Care	4.5	9.6	10.9	7.7	13.0
Other Products	(1.8)	(2.0)	(1.9)	(0.9)	0.4
Total	100.0	100.0	100.0	100.0	100.0
EBIT margin (%)					
Fabric Care	12.3	15.1	18.4	19.5	22.1
Dishwashing	13.2	15.4	15.3	17.5	20.0
Harraghald hagastisidas		(40.2)	(15.9)	(1.2)	(19.0)
Household Insecticides	(10.0)	(18.2)	(15.9)	(1.2)	(13.0)
Personal Care	(10.0)	10.1	15.3	13.3	
		· · · · · · · · · · · · · · · · · · ·		· · ·	18.2

Source: Company, MOFSL

Valuation and view

What has happened over the past 10 years?

- Given JYL (INR11.1b/INR24.9b revenue in FY13/FY23) is much smaller than its peers, its financial performance has been disappointing over the past 10 years.
- While it has reported a ~8.4% sales CAGR over this period, EBITDA/PAT CAGRS have been tepid at ~9.3%/~14.7%. Sales/EBITDA/PAT CAGRS of 8.3%/-4.2%/5.4% for the last five years were not significantly better.

- Growth has been restricted by: 1) higher penetration and regional dependence
 of its largest brand Ujala, and 2) limited success in achieving profitable growth in
 other categories/geographies outside South India.
- The expiry of the Henkel option, which could have added more brands to its portfolio, has also been a setback.
- Given the above factors, it is not surprising that the stock has been an underperformer in recent years.

Our view on the stock

- We raise our EPS estimates for FY24/FY25 by 8%/5%.
- For a company that had lower sales of INR24.9b in FY23 (vs. its peers), its performance over the past five years has been consistently lackluster (at 8.3%/4.2% sales/operating profit CAGR).
- Despite healthy EBITDA growth in 1QFY24, JYL's EBITDA CAGRs for the 3 years and 5 years ending in FY24 are expected to remain in single digits. Despite assuming consolidated EBITDA margins close to their peak level in FY25, RoE remains lower than peers' at ~21%.
- We do not expect a major rerating anytime soon. We reiterate our Neutral stance on the stock with a TP of INR305 (21xFY25 target EV/ EBITDA).

Exhibit 2: We raise our FY24E/FY25E EPS by 8%/5%

	New		C	ld	Change (%)		
	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E	
Sales	28,060	31,176	27,685	30,542	1.4%	2.1%	
EBITDA	4,340	5,030	4,070	4,758	6.6%	5.7%	
PAT	3,196	3,727	2,956	3,548	8.1%	5.0%	





Source: Company, MOFSL Source: Company, MOFSL

 $Motilal\ Oswal$ Jyothy Laboratories

Financials and valuations

Y/E March	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Total Income from Operations	16,724	18,136	17,112	19,091	21,965	24,860	28,060	31,176
Change (%)	-0.6	8.4	-5.6	11.6	15.1	13.2	12.9	11.1
Gross Profit	7,971	8,429	8,103	8,987	9,135	10,511	13,067	14,788
Margin (%)	47.7	46.5	47.4	47.1	41.6	42.3	46.6	47.4
Total Expenditure	14,149	15,325	14,601	15,946	19,483	21,702	23,720	26,146
As a percentage of Sales	84.6	84.5	85.3	83.5	88.7	87.3	84.5	83.9
EBITDA	2,575	2,811	2,511	3,145	2,482	3,159	4,340	5,030
Margin (%)	15.4	15.5	14.7	16.5	11.3	12.7	15.5	16.1
Depreciation	311	306	529	556	582	501	626	649
EBIT	2,263	2,505	1,982	2,589	1,901	2,657	3,715	4,381
Int. and Finance Charges	481	352	329	192	118	131	137	148
Other Income	625	278	203	185	187	395	417	438
PBT bef. EO Exp.	2,407	2,430	1,856	2,581	1,969	2,922	3,995	4,671
EO Items	0	0	-38	-235	0	70	0	(
PBT after EO Exp.	2,407	2,430	1,818	2,346	1,969	2,992	3,995	4,671
Current Tax	619	454	189	440	378	595	799	943
Tax Rate (%)	25.7	18.7	10.4	18.7	19.2	19.9	20.0	20.2
Adjusted PAT	1,789	1,976	1,667	2,142	1,591	2,327	3,196	3,727
Change (%)	-12.4	10.5	-15.6	28.5	-25.7	46.2	37.3	16.6
Consolidated - Balance Sheet								(INR m)
Y/E March	FY18	FY19	FY20	FY21	FY22	FY23	FY23	FY25E
Equity Share Capital	182	367	367	367	367	367	367	367
Total Reserves	11,260	12,898	11,919	13,918	14,068	15,123	16,481	17,809
Net Worth	11,442	13,265	12,286	14,286	14,435	15,490	16,848	18,176
Minority Interest	-139	-215	-291	-379	-407	21	21	21
Deferred Liabilities	-902	-928	-1,027	-962	-907	-845	-845	-845
Total Loans	5,441	2,809	2,830	1,169	1,265	0	0	(
Capital Employed	15,841	14,932	13,798	14,114	14,387	14,665	16,024	17,352
Gross Block	11,762	12,046	13,050	13,556	13,764	14,125	14,325	14,525
Less: Accum. Deprn.	855	1,040	1,558	2,089	2,546	2,962	3,588	4,237
Net Fixed Assets	10,907	11,006	11,492	11,467	11,218	11,163	10,738	10,288
Capital WIP	153	143	245	101	76	155	123	123
Total Investments	1,132	1,044	0	0	0	0	0	C
Curr. Assets, Loans&Adv.	6,695	6,301	5,598	7,029	8,027	8,454	11,497	14,331
Inventory	1,836	1,974	2,251	2,786	2,972	3,019	3,928	4,365
Account Receivables	1,674	1,534	1,224	944	1,431	1,378	1,403	1,559
Cash and Bank Balance	1,367	964	289	1,938	2,112	2,835	3,525	5,474
Loans and Advances & Others	1,818	1,830	1,834	1,361	1,512	1,222	2,641	2,934
Curr. Liability & Prov.	3,045	3,563	3,537	4,483	4,933	5,107	6,334	7,391
Account Payables	1,720	2,134	1,450	2,143	2,364	2,143	2,806	3,118
Other Current Liabilities	663	715	1,299	1,520	1,767	2,037	2,546	3,182
Provisions	663	715	788	820	802	927	982	1,091
Net Current Assets Appl. of Funds	3,650	2,738	2,061	2,546	3,093	3,347	5,163	6,940
	15,841	14,932	13,798	14,114	14,387	14,665	16,024	17,352

E: MOFSL Estimates

Financials and valuations

Y/E March	FY18	FY19	FY20	FY21	FY22	FY23	FY24E	FY25E
Basic (INR)								
EPS	4.9	5.4	4.5	5.8	4.3	6.3	8.7	10.1
Cash EPS	5.7	6.2	6.0	7.3	5.9	7.7	10.4	11.9
BV/Share	31.2	36.1	33.5	38.9	39.3	42.2	45.9	49.5
DPS	0.5	6.0	0.0	4.0	2.5	3.0	4.0	5.4
Payout (%)	12	134	0	83	70	57	56	64
Valuation (x)								
P/E	59.7	54.0	64.0	49.8	67.1	45.9	33.4	28.6
Cash P/E	50.8	46.8	48.6	39.6	49.1	37.7	27.9	24.4
P/BV	9.3	8.0	8.7	7.5	7.4	6.9	6.3	5.9
EV/Sales	3.3	5.9	6.4	5.6	4.8	4.2	3.7	3.2
EV/EBITDA	21.7	38.3	43.5	33.7	42.7	32.9	23.8	20.1
Dividend Yield (%)	0.2	2.1	0.0	1.4	0.9	1.0	1.4	1.9
FCF per share	13.6	7.2	3.5	10.3	4.9	8.6	6.0	11.1
Return Ratios (%)						5.5		
RoE	16.0	16.0	13.0	16.1	11.1	15.6	19.8	21.3
RoCE	13.1	13.7	12.6	14.7	10.8	15.7	20.4	22.0
RoIC	12.7	15.7	13.6	16.6	12.7	17.8	24.7	29.0
Working Capital Ratios			20.0			27.0		
Asset Turnover (x)	1.1	1.2	1.2	1.4	1.5	1.7	1.8	1.8
Debt/Equity	0.5	0.2	0.2	0.1	0.1	0.0	0.0	0.0
Consolidated - Cash Flow Statemer Y/E March	nt FY18	FY19E	FY20	FY21	FY22	FY23	FY24E	(INR m) FY25E
OP/(Loss) before Tax	2,407	2,430	1,815	2,346	1,969	2,992	3,995	4,671
Depreciation	311	306	529	556	582	501	626	649
Interest & Finance Charges	413	314	304	161	82	54	137	148
Other income	-409	-25	-21	232	-36	-197	-477	-438
Direct Taxes Paid	-251	-418	-386	-327	-313	-567	-799	-436 -943
(Inc)/Dec in WC	-38	409	-527	1,055	-259	502	-1,126	172
CF from Operations	2,434	3,016	1,715	4,022	2,025	3,286	2,356	4,258
Ci ironi Operations	2,434	3,010	1,713	4,022	2,023	3,200	2,330	4,230
CF from Operating incl EO	2,434	3,016	1,715	4,022	2,025	3,286	2,356	4,258
(inc)/dec in FA	43	-383	-415	-257	-214	-122	-168	-200
· //								
(Pur)/Sale of Investments	-807	112		0	0	0	0	0
(Pur)/Sale of Investments Others			1,061	0			0 417	
Others	115	112 37	1,061 4	0 45	29	65	417	438
<u>, , , , , , , , , , , , , , , , , , , </u>		112	1,061	0				438 238
Others CF from Investments Issue of Shares	115 - 649	112 37 -234	1,061 4 650	0 45 -212 0	29 -185	65 - 57 0	417 249	438 238 0
Others CF from Investments	115 - 649 600	112 37 -234 4	1,061 4 650 0	0 45 -212	29 - 185 0	65 - 57	417 249 0	438 238 0
Others CF from Investments Issue of Shares (Inc)/Dec in Debt	115 - 649 600 2,276	112 37 -234 4 -610	1,061 4 650 0 41	0 45 -212 0 -1,669	29 - 185 0 100	65 - 57 0 -1,250	417 249 0 0	438 238 0 0 -148
Others CF from Investments Issue of Shares (Inc)/Dec in Debt Interest Paid	115 - 649 600 2,276 -600	112 37 -234 4 -610 -342	1,061 4 650 0 41 -212	0 45 -212 0 -1,669 -281	29 - 185 0 100 -74	65 - 57 0 -1,250 -104	417 249 0 0 -137	438 238 0 0 -148 -2,399
Others CF from Investments Issue of Shares (Inc)/Dec in Debt Interest Paid Dividend Paid	115 -649 600 2,276 -600 -1,090	112 37 -234 4 -610 -342 -182	1,061 4 650 0 41 -212 -2,656	0 45 -212 0 -1,669 -281	29 -185 0 100 -74 -1,469	65 -57 0 -1,250 -104 -918	417 249 0 0 -137 -1,777	438 238 0 0 -148 -2,399
Others CF from Investments Issue of Shares (Inc)/Dec in Debt Interest Paid Dividend Paid Others	115 -649 600 2,276 -600 -1,090 -2,639	112 37 -234 4 -610 -342 -182 -2,055	1,061 4 650 0 41 -212 -2,656 -211	0 45 -212 0 -1,669 -281 0	29 -185 0 100 -74 -1,469 -224	65 -57 0 -1,250 -104 -918 -235	417 249 0 0 -137 -1,777 0	438 238 0 0 -148 -2,399 0 -2,548
Others CF from Investments Issue of Shares (Inc)/Dec in Debt Interest Paid Dividend Paid Others CF from Fin. Activity	115 -649 600 2,276 -600 -1,090 -2,639 -1,453	112 37 -234 4 -610 -342 -182 -2,055 -3,185	1,061 4 650 0 41 -212 -2,656 -211 -3,039	0 45 -212 0 -1,669 -281 0 -212 -2,161	29 -185 0 100 -74 -1,469 -224 -1,667	65 -57 0 -1,250 -104 -918 -235 -2,507	417 249 0 0 -137 -1,777 0 -1,915	0 438 238 0 0 -148 -2,399 0 -2,548 1,949

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	<-10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinere

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage transactions. Details of pending Enquiry Proc llaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx Enquiry Proceedings Motilal Oswal Limited Financial Services available of are

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

Disclosures

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the 1934 act 1934 act 1934) and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore
In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months 6
- MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or
- act as an advisor or lender/borrower to such company(ies) received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

25 July 2023

9

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell

Offevarioe Neuressai Cell.		
Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products. Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.